Avalo Therapeutics, Inc. – NASDAQ:AVTX
Avalo Therapeutics stock price today
$8.9
+0.57
+6.84%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Avalo Therapeutics stock price monthly change
-31.50%
month
Avalo Therapeutics stock price quarterly change
-31.50%
quarter
Avalo Therapeutics stock price yearly change
+15919.23%
year
Avalo Therapeutics key metrics
Market Cap | 90.98M |
Enterprise value | 32.50M |
P/E | -0.54 |
EV/Sales | 1.60 |
EV/EBITDA | -0.44 |
Price/Sales | 1.29 |
Price/Book | -2.40 |
PEG ratio | -0.01 |
EPS | -318.9 |
Revenue | N/A |
EBITDA | -19.98M |
Income | -142.87M |
Revenue Q/Q | -100% |
Revenue Y/Y | -91.64% |
Profit margin | -378.61% |
Oper. margin | -366.98% |
Gross margin | 71.76% |
EBIT margin | -366.98% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAvalo Therapeutics stock price history
Avalo Therapeutics stock forecast
Avalo Therapeutics financial statements
| Jun 2023 | 643K | -8.19M | -1274.18% |
|---|---|---|---|
| Sep 2023 | 236K | -5.22M | -2215.25% |
| Dec 2023 | 571K | -8.16M | -1430.47% |
| Mar 2024 | 0 | -121.29M |
| 2025 | 1M | -36M | -3600% |
|---|---|---|---|
| 2026 | 1M | -39M | -3900% |
| 2027 | 1M | -313.83K | -31.38% |
| 2028 | 1.70M | -341.60K | -20.03% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 24235000 | 31.20M | 128.76% |
|---|---|---|---|
| Sep 2023 | 29270000 | 14.57M | 49.8% |
| Dec 2023 | 20993000 | 13.68M | 65.21% |
| Mar 2024 | 123728000 | 224.81M | 181.7% |
| Jun 2023 | -11.02M | 158K | 598K |
|---|---|---|---|
| Sep 2023 | -6.83M | 0 | 10.69M |
| Dec 2023 | -2.76M | -158K | 1K |
| Mar 2024 | -6.20M | 356K | 108.61M |
Avalo Therapeutics alternative data
| Sep 2023 | 20 |
|---|---|
| Oct 2023 | 20 |
| Nov 2023 | 20 |
| Dec 2023 | 20 |
| Jan 2024 | 20 |
| Feb 2024 | 20 |
| Mar 2024 | 20 |
| Apr 2024 | 20 |
| May 2024 | 19 |
| Jun 2024 | 19 |
| Jul 2024 | 19 |
Avalo Therapeutics other data
2.18%
-97.82%
of AVTX is owned by hedge funds
13
-13
205.43K
-5.34M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 2083 | 0 |
| Feb 2023 | 900000 | 0 |
| Apr 2023 | 106329 | 0 |
| May 2023 | 68515 | 0 |
| Jun 2023 | 1651996 | 3683542 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ARMISTICE CAPITAL, LLC 10 percent owner | Common Stock | 937,404 | $0.52 | $486,513 | ||
Sale | ARMISTICE CAPITAL, LLC 10 percent owner | Common Stock | 2,746,138 | $0.61 | $1,683,383 | ||
Purchase | CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner | Common Stock | 1,608,000 | $0.63 | $1,016,256 | ||
Purchase | CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner | Common Stock | 2,000 | $4.14 | $8,288 | ||
Purchase | CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner | Common Stock | 3,000 | $3.91 | $11,715 | ||
Purchase | CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner | Common Stock | 3,160 | $3.68 | $11,641 | ||
Purchase | CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner | Common Stock | 6,000 | $3.48 | $20,874 | ||
Purchase | CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner | Common Stock | 8,750 | $3.82 | $33,443 | ||
Purchase | CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner | Common Stock | 2,149 | $4.34 | $9,316 | ||
Purchase | SULLIVAN CHRISTOPHER RYAN officer: Chief Fi.. | Common Stock | 511 | $3.42 | $1,748 |
-
What's the price of Avalo Therapeutics stock today?
One share of Avalo Therapeutics stock can currently be purchased for approximately $8.9.
-
When is Avalo Therapeutics's next earnings date?
Unfortunately, Avalo Therapeutics's (AVTX) next earnings date is currently unknown.
-
Does Avalo Therapeutics pay dividends?
No, Avalo Therapeutics does not pay dividends.
-
How much money does Avalo Therapeutics make?
Avalo Therapeutics has a market capitalization of 90.98M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 89.34% to 1.92M US dollars.
-
What is Avalo Therapeutics's stock symbol?
Avalo Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "AVTX".
-
What is Avalo Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Avalo Therapeutics?
Shares of Avalo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Avalo Therapeutics's key executives?
Avalo Therapeutics's management team includes the following people:
- Dr. Garry A. Neil M.D. Chief Scientific Officer(age: 71, pay: $705,480)
- Dr. H. Jeffery Wilkins M.D. Chief Medical Officer(age: 63, pay: $547,420)
- Mr. Michael F. Cola Chief Executive Officer & Director(age: 65, pay: $464,990)
-
How many employees does Avalo Therapeutics have?
As Jul 2024, Avalo Therapeutics employs 19 workers, which is 5% less then previous quarter.
-
When Avalo Therapeutics went public?
Avalo Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 14 Oct 2015.
-
What is Avalo Therapeutics's official website?
The official website for Avalo Therapeutics is avalotx.com.
-
Where are Avalo Therapeutics's headquarters?
Avalo Therapeutics is headquartered at 540 Gaither Road, Rockville, MD.
-
How can i contact Avalo Therapeutics?
Avalo Therapeutics's mailing address is 540 Gaither Road, Rockville, MD and company can be reached via phone at +41 05228707.
Avalo Therapeutics company profile:
Avalo Therapeutics, Inc.
avalotx.comExchange:
NASDAQ
Full time employees:
19
Industry:
Biotechnology
Sector:
Healthcare
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
540 Gaither Road
Rockville, MD 20850
Rockville, MD 20850
CIK: 0001534120
ISIN: US05338F3064
CUSIP: 05338F108
